Welcome to our dedicated page for Lyra Therapeutics news (Ticker: LYRA), a resource for investors and traders seeking the latest updates and insights on Lyra Therapeutics stock.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) is a clinical-stage biotechnology company whose news flow centers on the development and corporate status of its investigational sinonasal implant LYR-210 for chronic rhinosinusitis (CRS). Company press releases describe LYR-210 as a bioabsorbable implant designed for a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages for CRS patients who have failed medical management.
News updates from Lyra highlight key milestones in the ENLIGHTEN Phase 3 clinical program, including topline results from the ENLIGHTEN 2 trial. The company has reported that ENLIGHTEN 2 met its primary endpoint in adult CRS patients without nasal polyps, with statistically significant improvements in a composite of the three cardinal symptoms of CRS at week 24, as well as statistically significant gains in key secondary endpoints such as SNOT-22 scores. Additional releases discuss pooled analyses in patients with small nasal polyps and 52-week extension data from ENLIGHTEN 1, which the company describes as supporting a favorable safety profile and durable symptom control.
Investors and observers can also find news about Lyra’s regulatory interactions with the U.S. Food and Drug Administration (FDA), including written feedback and meetings that clarify potential paths toward a New Drug Application for specific CRS populations. Corporate and financial news items cover quarterly and annual results, restructuring charges, workforce reductions, and financing transactions such as a registered direct offering and concurrent private placement of warrants.
More recent corporate updates include announcements that the Board of Directors has decided to suspend further development of LYR-210, cease product development operations, and implement workforce reductions while the company evaluates strategic alternatives. For those tracking LYRA, the news stream provides context on clinical data, regulatory discussions, capital markets activity, and changes in Lyra’s operating plans over time.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 12:00 p.m. ET, featuring CEO Maria Palasis. The event can be accessed live through the company’s website. Lyra focuses on innovative therapies for ENT diseases, with lead product LYR-210 aimed at treating chronic rhinosinusitis. The company emphasizes the potential of its XTreo™ platform for sustained local drug delivery. A replay of the webcast will be available for 30 days post-event.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) reported Q3 2020 financial results, highlighting a cash position of $81.6 million, down from $86.6 million in Q2. R&D expenses rose to $3.7 million, while total operating expenses reached $6.4 million. The net loss for Q3 was $6.3 million, compared to $4.2 million in 2019. The company remains on track to announce topline Phase 2 results for LYR-210 in December, with positive clinical data suggesting significant anti-inflammatory effects for chronic rhinosinusitis. Dr. Nancy Snyderman has joined the board, enhancing strategic oversight.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) announced the appointment of Dr. Nancy L. Snyderman to its Board of Directors. Dr. Snyderman, an experienced otolaryngologist and healthcare expert, is expected to enhance Lyra's leadership as it approaches the topline results of the Phase 2 LANTERN study for its investigational drug LYR-210, aimed at treating chronic rhinosinusitis. Concurrently, Bob Langer and George Whitesides will transition from the Board to the Scientific Advisory Board. Lyra's ongoing focus is on developing novel drug delivery solutions for ENT diseases, particularly chronic rhinosinusitis.
Lyra Therapeutics (Nasdaq: LYRA) presented positive data on LYR-210 at the 66th Annual Meeting of the American Rhinologic Society. The data indicates a significant reduction in sinonasal Type 2 inflammation in patients with chronic rhinosinusitis (CRS) during a Phase 1 study. Notably, LYR-210 showed promising results in alleviating CRS symptoms and reducing local tissue inflammation. The company anticipates top-line results from its ongoing Phase 2 LANTERN study by the end of this year. These advancements demonstrate LYR-210’s potential as a novel treatment option for CRS, affecting millions of patients.
Lyra Therapeutics (Nasdaq: LYRA) announced its participation in the 66th Annual Meeting of the American Rhinologic Society, held virtually on September 10 and 12, 2020. The company will showcase three e-posters highlighting its lead product candidate, LYR-210, for chronic rhinosinusitis (CRS). These presentations will cover the product's efficacy in reducing sinonasal inflammation and symptoms. LYR-210 is a bioresorbable implant designed for up to six months of continuous drug delivery, aiming to provide a non-invasive treatment alternative for CRS patients.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) announced that CEO Maria Palasis, Ph.D., will present at the BTIG Virtual Biotechnology Conference on August 11, 2020, at 12:30 p.m. ET. The company focuses on developing integrated drug and delivery solutions for ear, nose, and throat diseases using its innovative XTreo™ platform. Initial product candidates, LYR-210 and LYR-220, aim to treat chronic rhinosinusitis (CRS) via a minimally invasive procedure. Approximately 14 million people in the U.S. are affected by CRS, and Lyra is advancing LYR-210 through a Phase 2 clinical trial.
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company, will have its President and CEO, Maria Palasis, participate in a fireside chat at the William Blair Biotech Focus Conference on August 6, 2020, at 10:00 a.m. ET. The conference will be accessible via a live audio webcast on Lyra's Investor Relations page. Lyra specializes in developing innovative drug delivery solutions for ear, nose, and throat diseases, notably chronic rhinosinusitis, with products LYR-210 and LYR-220 aimed at providing sustained therapy.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) reported its Q1 2020 financial results and corporate updates, marking significant achievements. The company closed its IPO, raising approximately $64 million from the sale of 4,025,000 shares at $16.00 each, with trading starting on May 1, 2020. Additionally, it completed a Series C financing, securing $30 million to advance its clinical programs. Despite FDA clearance for LYR-210's Phase 2 trial, enrollment was halted due to COVID-19, shifting to remote assessments. As of March 31, 2020, cash reserves were $35.2 million, with a net loss of $4.2 million for the quarter.